Successful Patient-Derived Organoid Culture of Gynecologic Cancers for Disease Modeling and Drug Sensitivity Testing.
Simple Summary: In the conventional treatment of gynecologic malignancies, most patients receive similar 'one-size-fits-all' treatment. However, it is increasingly clear that standard therapies do not work in every patient, and it would be very helpful to have pretreatment predictive assays to provi...
| Publicado en: | Cancers Vol. 13; no. 12; pp. 2901 - 2902 |
|---|---|
| Autores principales: | , , , , , , |
| Formato: | pictorial research tables/charts Journal Article |
| Publicado: |
MDPI
Jun2021
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=151146068&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 151146068 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 20726694 B74B jtl: Cancers issn: 20726694 maglogo: N pubinfo: dt: Jun2021 vid: 13 iid: 12 pid: 97109 pub: MDPI artinfo: ui: 151146068 151146068 151146068 10.3390/cancers13122901 151146068 ppf: 2901 ppct: 1 formats: tig: atl: Successful Patient-Derived Organoid Culture of Gynecologic Cancers for Disease Modeling and Drug Sensitivity Testing. aug: au: Bi, Jianling Newtson, Andreea M. Zhang, Yuping Devor, Eric J. Samuelson, Megan I. Thiel, Kristina W. Leslie, Kimberly K. affil: Department of Obstetrics and Gynecology, University of Iowa, Iowa City, IA 52242, USA sug: subj: Tissue Culture Techniques Endometrial Neoplasms Ovarian Neoplasms Models, Biological Drug Screening Assays, Antitumor Drug Tolerance Human Cell Viability Antineoplastic Agents Individualized Medicine Chemotherapy, Cancer ab: Simple Summary: In the conventional treatment of gynecologic malignancies, most patients receive similar 'one-size-fits-all' treatment. However, it is increasingly clear that standard therapies do not work in every patient, and it would be very helpful to have pretreatment predictive assays to provide more personalized regimens. In this study, we describe the routine, successful establishment of patient-derived organoid models (PDOs) of endometrial and ovarian cancer tissues from consenting patients and provide an example of how information from drug screening in PDOs may be a useful predictor of patient response to therapy. Developing reliable experimental models that can predict clinical response before treating the patient is a high priority in gynecologic cancer research, especially in advanced or recurrent endometrial and ovarian cancers. Patient-derived organoids (PDOs) represent such an opportunity. Herein, we describe our successful creation of 43 tumor organoid cultures and nine adjacent normal tissue organoid cultures derived from patients with endometrial or ovarian cancer. From an initial set of 45 tumor tissues and seven ascites fluid samples harvested at surgery, 83% grew as organoids. Drug sensitivity testing and organoid cell viability assays were performed in 19 PDOs, a process that was accomplished within seven days of obtaining the initial surgical tumor sample. Sufficient numbers of cells were obtained to facilitate testing of the most commonly used agents for ovarian and endometrial cancer. The models reflected a range of sensitivity to platinum-containing chemotherapy as well as other relevant agents. One PDO from a patient treated prior to surgery with neoadjuvant trastuzumab successfully predicted the patient's postoperative chemotherapy and trastuzumab resistance. In addition, the PDO drug sensitivity assay identified alternative treatment options that are currently used in the second-line setting. Our findings suggest that PDOs could be used as a preclinical platform for personalized cancer therapy for gynecologic cancer patients. pubtype: Academic Journal doctype: pictorial research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|